Effects of a Novel Glucokinase Activator, Dorzagliatin, on Glycemic Control and Glucose Fluctuation in Drug-Naïve Patients with Type 2 Diabetes Mellitus.
Yuming WangXiaofei SuWenli ZhangYunting ZhouXiao ZhouWei YangHui-Qin LiJian-Hua MaPublished in: International journal of endocrinology (2023)
This study suggests that dorzagliatin therapy could effectively improve glycemic control and glucose fluctuation in drug-naïve patients with T2DM.
Keyphrases
- glycemic control
- blood glucose
- type diabetes
- end stage renal disease
- weight loss
- insulin resistance
- chronic kidney disease
- ejection fraction
- newly diagnosed
- peritoneal dialysis
- nuclear factor
- mesenchymal stem cells
- patient reported outcomes
- metabolic syndrome
- inflammatory response
- drug induced
- electronic health record